Patents Assigned to Bristol-Myers Squibb
  • Monoclonal antibodies to human CD6
    Patent number: 6372215
    Abstract: The invention provides antibodies and other binding agents that bind specifically to SRCR domains of human CD6 (hCD6) and have advantageous properties, including the capacity to substantially inhibit binding of activated leukocyte adhesion molecule (ALCAM) to hCD6. The binding agents of the invention are useful, inter alia, in methods for screening peptides and drugs that also bind to hCD6 and/or modulate ALCAM binding to hCD6, as well as in diagnostic and therapeutic methods for management and treatment of inflammatory and autoimmune diseases.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: April 16, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gary C. Starling, Anthony W. Siadak, Michael A. Bowen, Alejandro A. Aruffo, Jurgen Bajorath, Dale L. Bodian, John E. Skonier
  • Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
    Patent number: 6369103
    Abstract: A method is provided for preventing or reducing the risk of onset of a cardiovascular event by administering an HMG CoA reductase inhibitor such as pravastatin, to a patient which has one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia.
    Type: Grant
    Filed: January 18, 1994
    Date of Patent: April 9, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bruce D. Behounek, Mark E. McGovern, Adeoye Y. Olukotun
  • Thrombin or factor Xa inhibitors
    Patent number: 6369227
    Abstract: This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: April 9, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark, Renhau Li, Donald J. P. Pinto
  • Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
    Patent number: 6365749
    Abstract: The present invention relates to a process to produce ring opened epothilones and the novel ring opened epothilones produced thereform.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: April 2, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soong-Hoon Kim, Robert M. Borzilleri
  • Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
    Patent number: 6365589
    Abstract: The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula I: wherein A and B can be C or N and D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 2, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Methods for the preparation of taxanes using oxazolidine intermediates
    Patent number: 6365750
    Abstract: Novel oxazolidines finding utility as intermediates in the preparation of C-13 acyloxy sidechain-bearing taxanes such as paclitaxel and analogs thereof. The present invention also relates to novel methods of coupling the oxazolidines to form the aforementioned taxanes, and to methods of preparing the oxazolidines.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: April 2, 2002
    Assignee: Bristol Myers Squibb Comp.
    Inventors: John K. Thottathil, Ivan D. Trifunovich
  • Taxane anticancer agents
    Patent number: 6362217
    Abstract: The present invention concerns novel 7-deoxy taxane derivatives their use as antitumor agents, and pharmaceutical formulations.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: March 26, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Wendy S. Schwartz, Paul M. Scola, Qiufen May Xue, Mark D. Wittman, Mu-Jen Wu
  • Water soluble prodrugs of azole compounds
    Patent number: 6362172
    Abstract: Water-soluble prodrugs of triazole antifungal compounds having a secondary or tertiary hydroxy group are provided. More particularly, new water-soluble triazole antifungal compounds are provided having the general formula wherein A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxyl group and R and R1 are as defined in the specification.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: March 26, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yasutsugu Ueda, John D. Matiskella, Jerzy Golik, Thomas W. Hudyma, Chung-Pin Chen
  • Imidazopyridines for the treatment of neurological disorders
    Patent number: 6362180
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: March 26, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard Gerald Wilde, Rajagopal Bakthavatchalam, James Peter Beck, Argyrios Georgious Arvanitis
  • Catalysts for asymmetric addition of organozinc regents to aldehydes and method for preparation
    Patent number: 6362344
    Abstract: Chiral aminoalcohol catalysts and methods for their preparation are provided. The first catalyst is prepared via selective hydrogenation of one of two benzene rings in a precursor. The aminoalcohol promotes the asymmetric addition of organozinc reagents to aldehydes to afford optically active alcohols or their esters. The second catalyst is prepared by selective dialkylation of 3-exo-aminoisoborneol with a 2-haloethyl ether. The aminoalcohol promotes the addition of organozinc reagents to aliphatic aldehydes containing a &bgr;-branch with greatly enhanced enantioselectivity relative to DAIB.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: March 26, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: William A. Nugent
  • Methods of preparing polyurethane adhesives, adhesives produced thereby and medical devices employing the same
    Patent number: 6359100
    Abstract: A polyurethane adhesive composition preferably having pressure sensitive characteristics that is non-cytotoxic and methods of making the same which is especially useful for medical applications such as ostomy and wound care.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: March 19, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Fritz Hostettler, Peter Wachtel
  • Water soluble prodrugs of azole compounds
    Patent number: 6359141
    Abstract: Water-soluble prodrugs of triazole antifungal compounds having a secondary or tertiary hydroxy group are provided. More particularly, new water-soluble triazole antifungal compounds are provided having the general formula wherein A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxyl group and n, R1 and R2 are as defined in the specification.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: March 19, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas W. Hudyma, Oak K. Kim, Xiaofan Zheng
  • Azolo triazines and pyrimidines
    Patent number: 6358950
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: March 19, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Liqi He, Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis
  • Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
    Publication number: 20020031510
    Abstract: The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
    Type: Application
    Filed: May 22, 2001
    Publication date: March 14, 2002
    Applicant: Bristol-Myers Squibb Company
    Inventors: Christian P. Larsen, Alejandro A. Aruffo, Diane L. Hollenbaugh, Peter S. Linsley, Jeffrey A. Ledbetter, Thomas C. Pearson
  • Orthopaedic bone plate
    Patent number: 6355042
    Abstract: An orthopaedic bone plate is coupled to a bone having an enlarged head at one end thereof which is attached to a shaft. The bone plate includes an elongate portion, a flared portion and an intermediate portion. The elongate portion is attachable to the bone shaft using a plurality of bone screws. The elongate portion generally defines a longitudinal axis. The flared portion is attachable to the bone head using at least one bone screw. The intermediate portion interconnects the elongate portion and the flared portion. The intermediate portion is structured and arranged to allow the elongate portion and the flared portion to move relative to each other in a direction transverse to the longitudinal axis when the elongate portion and the flared portion are attached to the bone.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: March 12, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert A. Winquist, Steve Benirschke, Paul Duwelius, James Goulet, Raymond Desjardins, David Templeman, John E. Meyers, Stanley W. Patterson, Gregory G. Price
  • Process for the preparation of a paclitaxel C-4 methyl carbonate analog
    Patent number: 6353120
    Abstract: A process for the synthesis of a C-4 methyl carbonate paclitaxel analog from 10-deacetylbaccatin III by the selective reduction of the acetate at the C-4 position of 10-deacetylbaccatin using Red-Al.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: March 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Joydeep Kant
  • CRF receptor antagonists and methods relating thereto
    Patent number: 6352990
    Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: March 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: James R. McCarthy
  • Storage stable tretinoin and 4-hydroxyanisole containing topical composition
    Patent number: 6353029
    Abstract: A long-term storage stable tretinoin and 4-hydroxyanisole composition contains low molecular weight polyethylene glycol, antioxidant, a chelating agent, lower alkanol and water. The chelating agent provides at least two of the functions of oxygen scavaging, free radical chain terminating and reducing. The composition has a pH of 2.5 to 5 and a water content of at least 12%.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: March 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Prakash V. Parab
  • Preparation of 3-substituted-4-arylquinolin-2-one derivatives
    Patent number: 6353119
    Abstract: The present invention relates to a process for the preparation of 3-substituted-4-arylquinolin-2-one derivatives from a substituted coumarin and using a photochemical cyclization method on a dihydrofuran intermediate.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gerard A. Crispino, Shaopeng Wang, Jun Li
  • Method for epoxidation of 3-methylenecyclopropanes
    Patent number: 6353122
    Abstract: The present invention provides a process for the expoxidation of a protected 3-methylene-(trans)-1,2,-hydroxymethylcyclopropane with cyclohexanone and potassium peroxymonosulfate and subsequent rearrangement to provide the corresponding cyclobutanone.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: March 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul R. Brodfuehrer, Thomas R. Sattleberg, Sr.